Life Science

ContactContact ConsultantOrganizer
China Insights Consultancy
China Insights ConsultancyChina Insights Consultancy (CIC) is headquartered in Shanghai, with offices in Hong Kong, Nanjing, Beijing, and Hangzhou, and branches in Shenzhen and Guangzhou. The current staff size has exceeded 300 people. CIC is a professional consulting firm serving corporate investment, financing and strategic development, providing comprehensive industry consulting and advisory services for companies in various industries to go public and finance on the capital market. It has helped numerous Chinese companies successfully go public overseas. At the same time, we provide comprehensive business due diligence services for private equity funds investing in China, helping them to discover real opportunities and avoid potential risks. In 2021, CIC ranked first among industry advisors in the Hong Kong and US IPO markets, completing IPO projects for leading companies including Li Auto, KE Holdings, Tuya, Didi, Baidu, Weibo, etc., and has extensive project experience in new energy and the circular economy. CIC’s projects are highly customized and it is the only industry consultant in the market that has completed GDR projects, with a deep understanding of the GDR service process. CIC has long-term cooperation with numerous buy-side funds and investment groups and brings a strong buy-side perspective to reflect a company’s investment value in industry reports. CIC has been established for over a decade. Rooted in China and serving clients globally, it upholds the philosophy of “letting knowledge create value” and provides professional, reliable consulting services. Its research covers nearly 1,000 sub-sectors, with consulting experience for more than 3,000 enterprises, and a database linking over 1,000,000 senior industry experts. CIC also provides comprehensive commercial due diligence and expert network services for private equity funds investing in China and other emerging markets. By leveraging diversified online and offline research methods and expert engagement, CIC helps clients obtain first-hand information to support investment and business decisions.
Categories
01China
02Consulting Services
03Life Sciences
Nov 18, 202202:31:07
Life Science
0:00
0:00
/
0:00
Details

The history of human development and the timeline of the fight against human diseases have never coincided, and the exploration of human life and health has never stopped, and every progress in life sciences is a continuous break of the upper limit of the ultimate length of human life. The vast field of life sciences is the scientific basis for trillions of dollars of innovative drugs, medical devices, medical services and other large markets, to which countless scientists and entrepreneurs have dedicated their time and efforts. From the R&D tools for small and medium-sized molecules and macromolecules in the field of medicine, to the cultivation equipment for cell and gene therapy, to the technological basis for minimally invasive, precise and intelligent diagnosis and treatment processes; from the emergence of life science tools to the continuous iterative breakthroughs in innovative materials and synthetic biology, to the outbreak of consumables in the industrial supply chain, all the participants in the upstream, downstream and downstream of the industry chain of life sciences will usher in a new era of innovation, driven and supported by the big market in China. Driven and supported by the big market of China, all participants in the upstream, midstream and downstream of the life science industry chain will usher in significant historical development opportunities.